kidney cancer

CT texture analysis may aid risk stratification of renal massesA recent study suggests experimental "texture analysis" of renal masses via computed tomography scan holds promise as a technique to allow more effective risk stratification.
New treatment for advanced kidney cancer approved
New treatment for advanced kidney cancer approvedFDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
Robotic radical nephrectomy sees steady increase in use"In the end, it is up to the surgeons who wish to continue to perform these robotic procedure to demonstrate their cost-effectiveness," writes Badar M. Mian, MD.
How kidney Ca management strategies compareAn updated guideline on localized kidney cancer as well as a look at active surveillance as initial management for renal masses <2 cm were among the noteworthy kidney cancer studies at the AUA annual meeting in Boston.
New products: Holmium laser increases stone ablation volumeOther products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more
Guidelines update: Bladder, kidney, prostate cancerThis article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
Active surveillance: A potential role in metastatic RCC?Results from a recent prospective trial suggest that active surveillance may be suitable for some patients with advanced renal cell carcinoma.
Study data may help risk stratify microhematuria DxA recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.
Oral agent improves survival in advanced RCC patientsOnce-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
Kidney Ca: Cytoreductive nephrectomy appears to be protectiveOther kidney cancer research included an 8-gene panel that was able to predict high tumor grade in biopsy specimens and a review of perioperative transfusion’s effect on recurrence-free and overall survival.